In preclinical studies, two common type 2 diabetes mellitus drugs (saxagliptin and sitagliptin), which prolong the NRF2 antioxidant response by inhibiting KEAP1C151 (a cysteine sensor causing constitutive NRF2 activation), increase the metastatic risk of several cancers. Here, NFE2L2 is linked to type 2 diabetes mellitus.